On September 24, 2024, led by President Wang Yan of Xiamen University Affiliated Cardiovascular Hospital, in collaboration with Professor Nicolo Piazza and Professor Jean Buithieu from the McGill University Health Centre in Canada, the team successfully performed a trans-femoral transseptal mitral valve replacement using HighLife®, marking the first enrollment at the trial center. The patient was a severe functional mitral regurgitation case. The procedure went smoothly, with the Looping process taking approximately 13 minutes and the total operation time about 70 minutes. This confirmed the feasibility and ease of use of HighLife® under the guidance of multimodal imaging assessment and standardized surgical procedures. The implanted artificial valve is ideally positioned and well-shaped, with immediate disappearance of mitral regurgitation post-operation and no left ventricular outflow tract obstruction. Currently, the trans-septal mitral valve replacement technique is at the forefront of global technological validation.